Morgan Stanley Increases Haleon (NYSE:HLN) Price Target to $10.95

Haleon (NYSE:HLN) had its price objective boosted by stock analysts at Morgan Stanley from $9.90 to $10.95 in a research report issued on Friday, Benzinga reports. The firm presently has an “overweight” rating on the stock. Morgan Stanley’s price target would indicate a potential upside of 4.78% from the stock’s current price.

HLN has been the subject of several other reports. Berenberg Bank began coverage on Haleon in a report on Tuesday, August 6th. They set a “buy” rating for the company. The Goldman Sachs Group downgraded Haleon from a “buy” rating to a “neutral” rating in a research note on Tuesday, August 6th. One analyst has rated the stock with a hold rating and four have given a buy rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $10.95.

Haleon Stock Performance

Shares of HLN opened at $10.45 on Friday. The stock has a 50 day moving average of $9.73 and a 200 day moving average of $8.85. The company has a market capitalization of $47.72 billion, a price-to-earnings ratio of 34.83, a PEG ratio of 3.10 and a beta of 0.26. Haleon has a 12 month low of $7.70 and a 12 month high of $10.76. The company has a current ratio of 0.84, a quick ratio of 0.58 and a debt-to-equity ratio of 0.44.

Haleon (NYSE:HLN) last released its earnings results on Thursday, August 1st. The company reported $0.08 EPS for the quarter, missing analysts’ consensus estimates of $0.09 by ($0.01). The business had revenue of $3.50 billion for the quarter, compared to the consensus estimate of $3.55 billion. Haleon had a return on equity of 13.15% and a net margin of 9.71%. During the same quarter in the previous year, the firm earned $0.08 earnings per share. As a group, sell-side analysts forecast that Haleon will post 0.46 earnings per share for the current year.

Hedge Funds Weigh In On Haleon

A number of large investors have recently made changes to their positions in HLN. AE Wealth Management LLC increased its holdings in Haleon by 6.1% during the 2nd quarter. AE Wealth Management LLC now owns 19,199 shares of the company’s stock worth $159,000 after acquiring an additional 1,098 shares during the period. Cardinal Capital Management raised its position in shares of Haleon by 2.5% in the second quarter. Cardinal Capital Management now owns 46,231 shares of the company’s stock worth $382,000 after buying an additional 1,140 shares in the last quarter. Endowment Wealth Management Inc. boosted its stake in Haleon by 9.9% during the second quarter. Endowment Wealth Management Inc. now owns 12,867 shares of the company’s stock valued at $106,000 after buying an additional 1,161 shares during the period. Portside Wealth Group LLC grew its position in Haleon by 2.7% during the second quarter. Portside Wealth Group LLC now owns 44,985 shares of the company’s stock worth $372,000 after buying an additional 1,182 shares in the last quarter. Finally, Lester Murray Antman dba SimplyRich increased its stake in Haleon by 2.9% in the 2nd quarter. Lester Murray Antman dba SimplyRich now owns 45,519 shares of the company’s stock worth $375,000 after acquiring an additional 1,301 shares during the last quarter. 6.67% of the stock is owned by institutional investors.

About Haleon

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.